|
THOC2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.25740529099971E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.55449999936519E-09 |
| Normal-vs-Stage2 |
2.36310000456541E-08 |
| Normal-vs-Stage3 |
2.16230033878162E-10 |
| Normal-vs-Stage4 |
4.74020001028919E-09 |
| Stage1-vs-Stage2 |
1.912550E-01 |
| Stage1-vs-Stage3 |
7.372300E-02 |
| Stage1-vs-Stage4 |
1.478570E-01 |
| Stage2-vs-Stage3 |
9.795000E-01 |
| Stage2-vs-Stage4 |
9.351200E-01 |
| Stage3-vs-Stage4 |
9.491200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.22449828054982E-11 |
| Normal-vs-AfricanAmerican |
7.60499999999942E-05 |
| Normal-vs-Asian |
3.449000E-04 |
| Caucasian-vs-AfricanAmerican |
8.417600E-01 |
| Caucasian-vs-Asian |
1.315420E-01 |
| AfricanAmerican-vs-Asian |
4.635800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.15929488231359E-11 |
| Normal-vs-Female |
2.97100011259488E-10 |
| Male-vs-Female |
1.950030E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.11710000431032E-08 |
| Normal-vs-Age(41-60Yrs) |
9.69310187670658E-11 |
| Normal-vs-Age(61-80Yrs) |
6.84320378141479E-11 |
| Normal-vs-Age(81-100Yrs) |
2.83440000359292E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.687570E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.241900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.839700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.267000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.868780E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.119600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.868400E-02 |
| Classical-VS-Follicular |
2.591600E-02 |
| Classical-VS-Other |
4.871400E-01 |
| Classical-VS-Normal |
7.95309995638149E-09 |
| Tall-VS-Follicular |
8.705600E-01 |
| Tall-VS-Other |
8.738600E-01 |
| Tall-VS-Normal |
2.14399999975967E-07 |
| Follicular-VS-Other |
9.576400E-01 |
| Follicular-VS-Normal |
1.67540004092359E-09 |
| Other-VS-Normal |
5.100000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.34200436821652E-11 |
| Normal-vs-N1 |
3.71139999999492E-06 |
| N0-vs-N1 |
2.471800E-01 |
|
|
